ZLAB Zai Lab Ltd

  1. Stocks
  2. Healthcare
  3. NASDAQ: ZLAB

Price (delayed)

$31.47

Market cap

$3.08B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$4.6

Enterprise value

$2.09B

Zai Lab ) is an innovative commercial stage biopharmaceutical company focused on bringing transformative medicines for cancer, infectious and autoimmune diseases to patients in China and around the world. To ...

Highlights
ZLAB's gross profit has surged by 53% year-on-year and by 16% since the previous quarter
Zai Lab's revenue has increased by 49% YoY and by 9% from the previous quarter
The debt has grown by 31% YoY but it has contracted by 2.3% from the previous quarter
The equity has contracted by 24% YoY and by 5% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.zailaboratory.com
Peers: OCUP

Key stats

What are the main financial stats of ZLAB
Market
Shares outstanding
97.91M
Market cap
$3.08B
Enterprise value
$2.09B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.95
Price to sales (P/S)
14.02
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
9.73
Earnings
Revenue
$215.04M
EBIT
-$443.29M
EBITDA
-$426.71M
Free cash flow
-$392.23M
Per share
EPS
-$4.6
Free cash flow per share
-$4.09
Book value per share
$10.68
Revenue per share
$2.24
TBVPS
$12.65
Balance sheet
Total assets
$1.22B
Total liabilities
$174.55M
Debt
$20.39M
Equity
$1.05B
Working capital
$984.49M
Liquidity
Debt to equity
0.02
Current ratio
8.04
Quick ratio
7.56
Net debt/EBITDA
2.32
Margins
EBITDA margin
-198.4%
Gross margin
65.6%
Net margin
-206.1%
Operating margin
-186.6%
Efficiency
Return on assets
-32.6%
Return on equity
-38%
Return on invested capital
-146.9%
Return on capital employed
-41%
Return on sales
-206.1%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ZLAB stock price

How has the Zai Lab stock price performed over time
Intraday
2.71%
1 week
-8.17%
1 month
-13.73%
1 year
-28.18%
YTD
2.51%
QTD
2.51%

Financial performance

How have Zai Lab's revenue and profit performed over time
Revenue
$215.04M
Gross profit
$141.02M
Operating income
-$401.24M
Net income
-$443.29M
Gross margin
65.6%
Net margin
-206.1%
The company's operating margin has surged by 62% YoY and by 39% QoQ
The net margin has soared by 58% YoY and by 32% from the previous quarter
ZLAB's gross profit has surged by 53% year-on-year and by 16% since the previous quarter
Zai Lab's revenue has increased by 49% YoY and by 9% from the previous quarter

Growth

What is Zai Lab's growth rate over time

Valuation

What is Zai Lab stock price valuation
P/E
N/A
P/B
2.95
P/S
14.02
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
9.73
The EPS has grown by 39% YoY and by 27% from the previous quarter
The equity has contracted by 24% YoY and by 5% from the previous quarter
The stock's P/B is 4.3% below its last 4 quarters average of 3.0
Zai Lab's revenue has increased by 49% YoY and by 9% from the previous quarter
ZLAB's price to sales (P/S) is 25% lower than its last 4 quarters average of 18.3

Efficiency

How efficient is Zai Lab business performance
Zai Lab's return on invested capital has surged by 66% YoY and by 2.1% QoQ
The ROS has soared by 58% YoY and by 32% from the previous quarter
The ROA has grown by 26% YoY and by 20% from the previous quarter
ZLAB's ROE is up by 24% YoY and by 20% QoQ

Dividends

What is ZLAB's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ZLAB.

Financial health

How did Zai Lab financials performed over time
The company's total liabilities fell by 24% YoY and by 9% QoQ
The total assets has contracted by 24% YoY and by 6% from the previous quarter
The debt is 98% less than the equity
Zai Lab's debt to equity has soared by 100% YoY
The debt has grown by 31% YoY but it has contracted by 2.3% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.